Mridul Datta1, Gary G Schwartz. 1. Wake Forest Baptist Medical Center, Departments of Cancer Biology, Urology, and Epidemiology and Prevention, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Abstract
BACKGROUND: Loss of bone mineral density is an unintended consequence of androgen deprivation therapy in men with prostate cancer. Supplementation with calcium and/or vitamin D in these men seems logical and is advocated by many lay and professional groups. METHODS: We reviewed guidelines for calcium and vitamin D supplementation and the results of clinical trials of calcium and vitamin D supplementation on bone mineral density in men with prostate cancer undergoing androgen deprivation therapy. RESULTS: Whether supplementation of men undergoing androgen deprivation therapy with calcium and/or vitamin D results in higher bone mineral density than no supplementation has not been tested. The results of 12 clinical trials show that, at the doses commonly recommended, 500-1,000 mg calcium and 200-500 IU vitamin D per day, men undergoing androgen deprivation lose bone mineral density. CONCLUSION: The doses of calcium and vitamin D that have been tested are inadequate to prevent loss of bone mineral density in men undergoing androgen deprivation therapy. In light of evidence that high levels of dietary calcium and calcium supplement use are associated with higher risks for cardiovascular disease and advanced prostate cancer, intervention studies should evaluate the safety as well as the efficacy of calcium and vitamin D supplementation in these men.
BACKGROUND: Loss of bone mineral density is an unintended consequence of androgen deprivation therapy in men with prostate cancer. Supplementation with calcium and/or vitamin D in these men seems logical and is advocated by many lay and professional groups. METHODS: We reviewed guidelines for calcium and vitamin D supplementation and the results of clinical trials of calcium and vitamin D supplementation on bone mineral density in men with prostate cancer undergoing androgen deprivation therapy. RESULTS: Whether supplementation of men undergoing androgen deprivation therapy with calcium and/or vitamin D results in higher bone mineral density than no supplementation has not been tested. The results of 12 clinical trials show that, at the doses commonly recommended, 500-1,000 mg calcium and 200-500 IU vitamin D per day, men undergoing androgen deprivation lose bone mineral density. CONCLUSION: The doses of calcium and vitamin D that have been tested are inadequate to prevent loss of bone mineral density in men undergoing androgen deprivation therapy. In light of evidence that high levels of dietary calcium and calcium supplement use are associated with higher risks for cardiovascular disease and advanced prostate cancer, intervention studies should evaluate the safety as well as the efficacy of calcium and vitamin D supplementation in these men.
Authors: Panagiota N Mitrou; Demetrius Albanes; Stephanie J Weinstein; Pirjo Pietinen; Philip R Taylor; Jarmo Virtamo; Michael F Leitzmann Journal: Int J Cancer Date: 2007-06-01 Impact factor: 7.396
Authors: Nirmala Bhoopalam; Steven C Campbell; Thomas Moritz; William R Broderick; Padmini Iyer; Anthony G Arcenas; Peter J Van Veldhuizen; Nicholas Friedman; Domenic Reda; Stuart Warren; Harinder Garewal Journal: J Urol Date: 2009-09-16 Impact factor: 7.450
Authors: M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith Journal: J Clin Oncol Date: 2007-03-20 Impact factor: 44.544
Authors: Ann E Kearns; Donald W Northfelt; Amylou C Dueck; Pamela J Atherton; Shaker R Dakhil; Kendrith M Rowland; Jyotsna Fuloria; Patrick J Flynn; Todor Dentchev; Charles L Loprinzi Journal: Support Care Cancer Date: 2009-05-27 Impact factor: 3.603
Authors: Abbas H Panju; Henriette Breunis; Angela M Cheung; Marc Leach; Neil Fleshner; Padraig Warde; Sarah Duff-Canning; Murray Krahn; Gary Naglie; Ian Tannock; George Tomlinson; Shabbir M H Alibhai Journal: BJU Int Date: 2008-10-24 Impact factor: 5.588
Authors: S M H Alibhai; H Z Mohamedali; H Gulamhusein; A H Panju; H Breunis; N Timilshina; N Fleshner; M D Krahn; G Naglie; I F Tannock; G Tomlinson; P Warde; S Duff Canning; A M Cheung Journal: Osteoporos Int Date: 2013-04-06 Impact factor: 4.507
Authors: Julia E Inglis; Isabel D Fernandez; Edwin van Wijngaarden; Eva Culakova; Jennifer E Reschke; Amber S Kleckner; Po-Ju Lin; Karen M Mustian; Luke J Peppone Journal: Nutr Cancer Date: 2020-09-11 Impact factor: 2.900